Loading...
•
Mar 31, 2023
AptarGroup Q1 2023 Earnings Report
Reported strong operational performance driven by Aptar’s Pharma and Beauty segments.
Key Takeaways
AptarGroup reported a positive start to 2023, with a 2% increase in reported sales and a 4% increase in core sales, driven by the Pharma and Beauty segments. Net income decreased by 12% to $55 million due to restructuring charges, while adjusted earnings per share increased by 2% to $0.95.
Reported sales grew 2% and core sales increased 4% driven by demand in Pharma and Beauty.
Aptar Pharma reported sales growth of 4% and core sales growth of 7%.
Aptar Beauty reported sales growth of 6% and core sales growth of 9%.
Adjusted earnings per share increased 2% to $0.95.
AptarGroup
AptarGroup
AptarGroup Revenue by Segment
Revenue by Segment
Aptar Pharma Revenue
CapyFin.comAptar Beauty Revenue
CapyFin.comAptar Closures Revenue
CapyFin.com Forward Guidance
Aptar expects earnings per share for the second quarter of 2023, excluding any restructuring expenses, changes in the fair value of equity investments and acquisition costs, to be in the range of $1.11 to $1.19.
Positive Outlook
- Strong momentum continuing
- Proprietary pharma dispensing devices are expected to grow
- Beauty solutions are expected to grow
- Injectables division’s performance should improve as the division moves past its ERP system implementation.
- Anticipate a gradual recovery in our Closures segment as customers, especially in North America, continue to work through their inventory.
Revenue & Expenses
Visualization of income flow from segment revenue to net income